Guggenheim Initiates Coverage on Urogen Pharma with Buy Rating

Urogen Pharma (URGN) received a new rating from Guggenheim analyst Kelsey Goodwin, who initiated coverage with a Buy rating and set a price target of $36.00. Goodwin has a 4-star rating with an average return of 36.4% and a 68.42% success rate. The company's shares closed at $19.40. URGN market cap is $911.9M and has a P/E ratio of -5.85. Corporate insider activity shows negative sentiment with an increase in insiders selling their shares over the past quarter.

Urogen Pharma Ltd. (URGN), an Israel-based biopharmaceutical company, has received a new rating from Guggenheim analyst Kelsey Goodwin. Goodwin initiated coverage with a Buy rating and set a price target of $36.00. Goodwin, who holds a 4-star rating with an average return of 36.4% and a 68.42% success rate, believes that Urogen Pharma's innovative technologies hold significant potential in the treatment of cancers and urologic diseases [2].

Urogen Pharma's shares closed at $19.40 on July 2, 2025. The company's market capitalization stands at $911.9 million, and its P/E ratio is -5.85. The company has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that enhances the therapeutic profiles of existing drugs. Its lead product candidates, MitoGel (UGN-101) and VesiGel (UGN-102), are formulated using this technology [1].

However, corporate insider activity indicates negative sentiment, with an increase in insiders selling their shares over the past quarter. This suggests that insiders may have concerns about the company's future prospects or recent developments.

Urogen Pharma's recent developments, including Goodwin's positive rating, could attract more investors. However, the negative insider activity and the company's high valuation suggest caution. Investors should closely monitor the company's progress and insider activity to make informed decisions.

References:
[1] https://investors.urogen.com/stock-information/stock-quote-chart
[2] https://www.marketscreener.com/news/piper-sandler-initiates-urogen-pharma-at-overweight-with-36-price-target-ce7c51ddd981f421